Delivery Order SPE2DB20D2002-SPE2DB25FL71G
Award Date 8/26/25
Potential Completion Date 8/27/25
Potential Value $143K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded a $9,236.60 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes. This competitively awarded, firm fixed-price contract represents a single delivery order fulfillment without set-aside provisions. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is a...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,886.40 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 12, 2024. This delivery order is part of an indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the...
- The Defense Logistics Agency awarded a delivery order valued at $22,056.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply procurement executed under a non-set-aside vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with a ceiling value of $110,915.56 under a firm fixed price contract type. This delivery order, which is not set-aside and was competitively awarded, represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. HEPLISAV-B is a hepatitis B vaccine, and this procurement...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...
- The Defense Logistics Agency awarded a delivery order valued at $15,164.64 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $3,228.20 with a completion date of August 29, 2025. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,699.20 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on open competition. Performance will be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $8,424.80 with a firm fixed price structure. The contract, which is not set-aside and was competitively awarded, carries an ultimate completion date of September 8, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $121,133.82, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML syringes. The contract has an ultimate completion date of April 10, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...